3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
7
CNS
7
Breast
7
Thoracic
5
Gastrointestinal
5
Dermatologic
4
Tumor-Agnostic
3
Genitourinary
3
Sarcoma
2
Head & Neck
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Waldenstrom Macroglobulinemia
1
Multiple Myeloma
1
Influenza, Human
1
Interventions
Dexamethasone
479
Lenalidomide
297
Cyclophosphamide
271
Bortezomib
267
Melphalan
212
Calcium Dobesilate
189
fludarabine phosphate
121
daratumumab
121
Peripheral Blood Stem Cell Transplantation
101
fludarabine
99
carfilzomib
98
Thalidomide
94
pomalidomide
92
Filgrastim
92
Whole-Body Irradiation
88
Mycophenolic Acid
88
Busulfan
80
Tacrolimus
75
Granulocyte Colony-Stimulating Factor
72
dexamethasone acetate
65
ixazomib
62
Cyclosporine
59
dexamethasone 21-phosphate
56
Antilymphocyte Serum
51
auricularum
50
isatuximab
44
Radiotherapy
41
Etoposide
40
Stem Cell Transplantation
39
Methotrexate
33
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Vaccines
×
Plasma cell
×
Clear all
NCT02566265
2019-01-30
SHIVERING 2
Yale University
Phase 2
Completed
122 enrolled
10 charts